G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
Apostolia Maria Tsimberidou,Jorge E. Cortes,Deborah A. Thomas,Guillermo Garcia-Manero,Srdan Verstovsek,Stephan Faderl,Maher Albitar,Hagop M. Kantarjian,Elihu H. Estey,Francis J. Giles +9 more
TL;DR: A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant or relapsed AML, finding MFAC is an effective regimen for refractory AML.
Journal ArticleDOI
Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild‐type TP53
Rashmi Kanagal-Shamanna,Carlos E. Bueso-Ramos,Bedia A. Barkoh,Gary Lu,Sa Wang,Guillermo Garcia-Manero,Saroj Vadhan-Raj,Daniela Hoehn,L. Jeffrey Medeiros,C. Cameron Yin +9 more
TL;DR: Isolated isochromosome (17q) is a rare cytogenetic abnormality in Philadelphia chromosome‐negative myeloid neoplasm, usually myelodysplastic and/or myeloproliferative neoplasms (MDS/MPN).
Journal ArticleDOI
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes
Koichi Takahashi,Koichi Takahashi,Feng Wang,Kiyomi Morita,Yuanqing Yan,Peter Hu,Pei Zhao,Abdallah Abou Zhar,Chang-Jiun Wu,Curtis Gumbs,Latasha Little,Samantha Tippen,Rebecca Thornton,Marcus Coyle,Marisela Mendoza,Erika Thompson,Jianhua Zhang,Courtney D. DiNardo,Nitin Jain,Farhad Ravandi,Jorge E. Cortes,Guillermo Garcia-Manero,Steven M. Kornblau,Michael Andreeff,Elias Jabbour,Carlos E. Bueso-Ramos,Akifumi Takaori-Kondo,Marina Konopleva,Keyur P. Patel,Hagop M. Kantarjian,P. Andrew Futreal +30 more
TL;DR: Genome-wide methylation comparison among MPAL, AML, B-ALL, and T-ALL sub-classifies MPAL into AML-type and ALL-type MPAL which is associated with better clinical response when lineage-matched therapy is given, and provides proof of concept for a molecularly guided precision therapy approach in MPAL.
Journal ArticleDOI
Therapy with azanucleosides for myelodysplastic syndromes
TL;DR: This article critically appraise the most relevant clinical data reported on the use of azanucleosides for the treatment of patients with MDS.
Journal ArticleDOI
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
Elias Jabbour,Hagop M. Kantarjian,Dan Jones,Neeli Reddy,Susan O'Brien,Guillermo Garcia-Manero,Jan A. Burger,Jorge E. Cortes +7 more
TL;DR: F317L mutation is resistant to dasatinib but sensitive to other TKIs, and the prognosis is dependent mostly on the disease stage.